

BRITISH SARCOMA GROUP

England & Wales · Charity number 1154928

Details

Status Registered

Legal form CIO

Registered 2013-12-08

Register [View on the Charity Commission register](#)

Contact

Address Unit 14 The Stottie Shed
Baker's Yard
Christon Road
Newcastle Upon Tyne
NE3 1XD

Phone 01912442581

Website www.britishsarcomagroup.org.uk

Activities

Objects: THE OBJECTS OF THE CIO ARE(1) THE RELIEF OF SICKNESS BY MAINTAINING AND ADVANCING THE EDUCATION OF MEDICAL, NURSING AND HEALTHCARE PROFESSIONALS IN THE UNITED KINGDOM CONCERNED WITH THE TREATMENT AND CARE OF PATIENTS WITH BONE AND SOFT TISSUE SARCOMAS, THROUGH THE PROVISION OF INFORMATION, TRAINING, AND THE IDENTIFICATION OF BEST PRACTICE;(2) THE RELIEF OF SICKNESS BY THE PROMOTION OF EXCELLENCE IN THE HEALTHCARE AND THE TREATMENT OF PATIENTS WITH BONE AND SOFT TISSUE SARCOMA, THROUGH ENABLING TREATMENT SPECIALISTS TO IDENTIFY AND SHARE BEST PRACTICE;(3) THE RELIEF OF SICKNESS AND THE PRESERVATION OF HEALTH IN PARTICULAR BY PROMOTING AND SUPPORTING RESEARCH WITH THE PUBLICATION OF THE USEFUL RESULTS THEREOF AND THE DEVELOPMENT OF MORE EFFECTIVE TREATMENT AND CARE FOR PATIENTS WITH BONE AND SOFT TISSUE SARCOMAS;(4) TO ADVANCE THE EDUCATION OF THE MEDICAL PROFESSION AND THE GENERAL PUBLIC IN ALL AREAS RELATING TO SARCOMA.

Activities: Provide best practice info in treatmentAnnual eventScientific meetingsGuidelines & service standardsNHS representation through responses & advisory group membershipProjects to improve healthcare & treatmentInform professionals about researchProvide info & training to medical professionalsWork with professionals & patients to develop joint educational initiatives & raise awareness

Classification

- **How:** Provides Services, Provides Advocacy/advice/information, Sponsors Or Undertakes Research
- **What:** General Charitable Purposes, Education/training, The Advancement Of Health Or Saving Of Lives
- **Who:** The General Public/mankind

Geography

- Northern Ireland
- Scotland

Finances

Period end	Income	Expenditure	Assets	Employees
2025-03-31	£184,451	£103,469	-	-
2024-03-31	£105,987	£97,659	-	-
2023-03-31	£107,130	£110,696	-	-
2022-03-31	£101,195	£99,410	-	-
2021-03-31	£32,250	£42,177	-	-

Trustees

Name	Role	Appointed
ANDREW JOHN HAYES		2013-10-22
Anant Desai		2022-03-22
Christine Anne Millman		2022-06-06
Debbie Louise Artis		2022-12-12
Dr Adam Dangoor		2014-04-23
Dr Alexander Thomas John Lee		2024-05-20
Dr Charlotte Benson		2024-05-20
Dr Sherron Furtado		2022-06-06
Johanne Vass		2024-05-20
Michael Christopher Parry		2025-12-15
Sian Elizabeth Alsousou		2024-05-20

Accounts

BRITISH SARCOMA GROUP

UNAUDITED

TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2025

BRITISH SARCOMA GROUP

CONTENTS

	Page
Reference and administrative details of the charity, its Trustees and advisers	1
Trustees' report	2 - 5
Independent examiner's report	6
Statement of financial activities	7
Balance sheet	8
Notes to the financial statements	9 - 18

BRITISH SARCOMA GROUP

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS
FOR THE YEAR ENDED 31 MARCH 2025**

Trustees

Mr A Desai, President from 5 March 2025
Dr A Dangoor, President up to 5 March 2025
Ms S E Alsousou
Ms D L Artis
Dr C Benson
Dr I Fragkandrea-Nixon (resigned 4 March 2025)
Dr S Furtado
Mr C Gerrand (resigned 9 June 2025)
Mr A Hayes
Dr A T J Lee
Ms C A Millman
Mr O Tilsley (resigned 4 March 2025)
Mr J Vass

Charity registered number

1154928

Principal office

Unit 14 The Stottie Shed
Baker's Yard
Christon Road
Newcastle upon Tyne
NE3 1XD

Secretary

Echo Events & Association Management

Accountants

Kinnair Associates Limited
Chartered Accountants
Aston House
Redburn Road
Newcastle upon Tyne
NE5 1NB

Bankers

Lloyds Bank Plc
Ariel House
2138 Coventry Road
Sheldon
Birmingham
B26 3JW

BRITISH SARCOMA GROUP

TRUSTEES' REPORT FOR THE YEAR ENDED 31 MARCH 2025

The Trustees present their annual report together with the financial statements of the charity for the year from 1 April 2024 to 31 March 2025.

The financial statements have been prepared in accordance with the accounting policies set out in the notes to the financial statements and comply with the charity's governing document, the Charities Act 2011 and the relevant version of the Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

Objectives and activities

● Policies and objectives

In setting objectives and planning for activities, the Trustees have given due consideration to general guidance published by the charity commission relating to public benefit.

The objectives of the British Sarcoma Group are: -

1. the relief of sickness by maintaining and advancing the education of medical, nursing and healthcare professionals in the United Kingdom concerned with the treatment and care of patients with bone and soft tissue sarcomas, through the provision of information, training and the identification of best practice;
2. the relief of sickness by the promotion of excellence in the healthcare and the treatment of patients with bone and soft tissue sarcoma, through enabling treatment specialists to identify and share best practice;
3. the relief of sickness and the preservation of health in particular by promoting and supporting research with the publication of the useful results thereof and the development of more effective treatment and care for patients with bone and soft tissue sarcomas; and
4. to advance the education of the medical profession and the general public in all areas relating to sarcoma.

● Main activities undertaken to further the charity's purposes for the public benefit

Providing information about best practice in sarcoma treatment via the website, email updates, reports and other publications.

Running a programme of training and educational events (conferences, workshops, study days) to identify and share best practice.

Running scientific meetings.

Developing and promoting nationally-recognised and adopted clinical guidelines and service standards for the management of sarcoma.

Providing expert representation on sarcoma to the NHS through written responses and membership of advisory groups.

Developing projects to improve sarcoma healthcare and treatment.

Informing medical professionals about new research; promoting opportunities for research; commissioning research into best practice.

BRITISH SARCOMA GROUP

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

Objectives and activities (continued)

Providing information and training to generalist medical professionals about sarcoma.

Working with other professional bodies and Royal Colleges to develop joint educational initiatives.

Working with national sarcoma patient organisations to raise awareness of sarcoma amongst public.

Achievements and performance

● Review of activities

During 2024 the BSG successfully updated and published the following guidelines in the British Journal of Cancer-

- UK BSG Guidelines for the Management of Soft Tissue Sarcomas – 2024 Update
- UK Guidelines for the Management of Gastrointestinal Stromal Tumour (GIST) – 2024 Update
- UK BSG Guidelines for the Management of Bone Sarcomas – 2024 Update

We also completed and published updated Rehabilitation Guidelines to the Journal of Disability & Rehabilitation.

We held our annual conference on the 5th & 6th March 2025 at the Hilton, Newcastle Gateshead. The conference attracted a multidisciplinary group of around 300 sarcoma specialists from across the country with a programme featuring over 60 speakers as well as academic poster displays and exhibition. The exhibition attracts leading pharmaceutical and medical providers for the industry.

The Sarcoma SAG (Specialist Advisory Group) held a number of meetings through out the year both virtually and in person. These meetings are facilitated and supported by the BSG and bring SAG chairs together from across the country to share in updates and best practice. BSG members were also involved in work alongside charity partner Sarcoma UK to try and improve the early diagnosis of sarcoma.

Financial review

● Overview

Income for the year totalled £184,451 (2024 - £105,987). The 2025 year benefitted from unrestricted legacies of £89,897 although in most years the Statement of Financial Activities shows that the main source of income is sponsorship and delegate fees from the annual conference.

Delegate fees are shown under the general fund as unrestricted funds. Total delegate fees for the year were £59,149 : (2024 £60,627).

Sponsorship income is restricted at the request of the donor. Total sponsorship for the year was £34,966 (2024 - £40,005). A full breakdown of sponsors is given in the notes to the financial statements.

Expenditure for the year totalled £103,604 (2024 - £97,659) with the main item of charitable expenditure being in relation to the annual conference.

A surplus of £80,847 (previous year: surplus of £8,328) was achieved this year and increases the total funds of the charity at the year end to £190,086 (previous period: £109,239).

BRITISH SARCOMA GROUP

**TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025**

• Going concern

After making appropriate enquiries, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. For this reason, they continue to adopt the going concern basis in preparing the financial statements. Further details regarding the adoption of the going concern basis can be found in the Accounting Policies.

• Reserves policy

The total funds of the charity at the year end were £190,086.

The Board of Trustees have agreed it is necessary to maintain a level of reserves to cover the administration costs and 50% of the cost of staging the annual conference. This averages approximately £70,000 in total. The Trustees are pleased to note that the total funds exceed this figure, largely due to the legacies received of £89,897 and have plans to use these as explained in the future developments section of this Report.

Structure, governance and management**• Constitution**

The British Sarcoma Group (BSG) is a Charitable Incorporated Organisation (CIO) registered in England and Wales with the Charity Commission on 8 December 2013 with registration number 1154928. Its governing document is its constitution, adopted on 22 May 2013.

• Methods of appointment or election of Trustees

Trustees are appointed by the existing Trustees for a three-year term which is extendable by mutual agreement of other Trustees with a maximum extension of a further three years. This is dependent on the skill set offered by the board member and the need to retain a wide range of key skills relevant to the continued success of the charity. New Trustees receive the BSG constitution, published financial statements, minutes of previous Board of Trustee meetings, as well as the Charity Commission guidance on effective governance.

Trustees meet, on average, three times a year in person or by teleconference.

• Organisational structure and decision-making policies

The day-to-day administration of the British Sarcoma Group and BSG conference management is delivered by Echo AM Limited.

• Financial risk management

The Trustees have assessed the major risks to which the charity is exposed, in particular those related to the operations and finances of the charity, and are satisfied that systems and procedures are in place to mitigate exposure to the major risks.

BRITISH SARCOMA GROUP

**TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025**

Plans for future periods

In 2025/2026 we will be hosting our annual conference on the 25th & 26th February 2026 at the Oxford Town Hall, Oxford. This event continues to be the principle UK forum for multidisciplinary education in sarcoma. We will be reviewing options for offering educational grants or awards to members, and continuing to host regular SAG meetings which are an important platform for the dissemination and sharing of information. We will also continue to work with other charity partners to improve early diagnosis and treatment of patients with sarcoma.

We plan to launch a new website in 2026 and work has already started on this. We hope this will create an improved area for members to gather important information on BSG activities as well as more general updates on Sarcoma care.

Statement of Trustees' responsibilities

The Trustees are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charity's transactions and disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the Trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the members of the board of Trustees on 29 September 2025 and signed on their behalf by:

DocuSigned by:

B7F92F186D8546B...

Mr A Desai
President

BRITISH SARCOMA GROUP

**INDEPENDENT EXAMINER'S REPORT
FOR THE YEAR ENDED 31 MARCH 2025**

Independent examiner's report to the Trustees of British Sarcoma Group ('the charity')

We report to the charity Trustees on our examination of the accounts of the charity for the year ended 31 March 2025.

Responsibilities and basis of report

As the Trustees of the charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').

We report in respect of our examination of the charity's accounts carried out under section 145 of the 2011 Act and in carrying out our examination we have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

Your attention is drawn to the fact that the charity has prepared the financial statements in accordance with the relevant version of the Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). This is in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has been withdrawn.


We understand that this has been done in order for the accounts to provide a true and fair view in accordance with the Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2019.

We have completed our examination. We confirm that no matters have come to our attention in connection with the examination giving us cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 130 of the 2011 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

We have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

This report is made solely to the charity's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our work has been undertaken so that we might state to the charity's Trustees those matters we are required to state to them in an Independent examiner's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's Trustees as a body, for our work or for this report.

Signed: 
Detlev Anderson FCA

Dated: 29 September 2025

Kinnair Associates Limited
Chartered Accountants
Aston House
Redburn Road
Newcastle upon Tyne
NE5 1NB

BRITISH SARCOMA GROUP

STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 MARCH 2025

	Note	Unrestricted funds 2025 £	Restricted funds 2025 £	Total funds 2025 £	Total funds 2024 £
Income from:					
Donations and legacies	3	90,195	-	90,195	-
Charitable activities	4	59,149	34,966	94,115	105,987
Investments	5	141	-	141	-
Total income		149,485	34,966	184,451	105,987
Expenditure on:					
Charitable activities	6	68,503	34,966	103,469	97,659
Total expenditure		68,503	34,966	103,469	97,659
Net movement in funds		80,982	-	80,982	8,328
Reconciliation of funds:					
Total funds brought forward		109,239	-	109,239	100,911
Net movement in funds		80,982	-	80,982	8,328
Total funds carried forward		190,221	-	190,221	109,239

The Statement of financial activities includes all gains and losses recognised in the year.

The notes on pages 9 to 18 form part of these financial statements.

BRITISH SARCOMA GROUP

BALANCE SHEET
AS AT 31 MARCH 2025

	Note	2025 £	2024 £
Current assets			
Debtors	10	3,552	13,965
Cash at bank and in hand		219,196	176,724
		<u>222,748</u>	<u>190,689</u>
Current liabilities			
Creditors: amounts falling due within one year	11	(32,527)	(81,450)
		<u>190,221</u>	<u>109,239</u>
Net current assets			
		<u>190,221</u>	<u>109,239</u>
Total assets less current liabilities			
		<u>190,221</u>	<u>109,239</u>
Total net assets			
		<u><u>190,221</u></u>	<u><u>109,239</u></u>
Charity funds			
Restricted funds	13	-	-
Unrestricted funds	13	190,221	109,239
		<u>190,221</u>	<u>109,239</u>
Total funds			
		<u><u>190,221</u></u>	<u><u>109,239</u></u>

The financial statements were approved and authorised for issue by the Trustees on 29 September 2025 and signed on their behalf by:

DocuSigned by:

B7F92F186D8546B...

Mr A Desai
President

The notes on pages 9 to 18 form part of these financial statements.

BRITISH SARCOMA GROUP

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025**

1. General information

British Sarcoma Group is a charitable incorporated organisation, charity number 1154928. The registered office is Unit 14, The Stottie Shed, Baker's Yard, Christon Road, Newcastle upon Tyne, NE3 1XD.

2. Accounting policies**2.1 Basis of preparation of financial statements**

The financial statements have been prepared in accordance with the relevant version of the Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011 and UK Generally Accepted Accounting Practice.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair view'. This departure has involved following the relevant version of the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

British Sarcoma Group meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The financial statements are prepared in pounds Sterling and rounded to the nearest pound.

2.2 Going concern

The charity has cash resources and no requirement for external funding. The Trustees have reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. They continue to believe the going concern basis of accounting is appropriate in preparing the annual financial statements.

2.3 Income

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

The recognition of income from legacies is dependent on establishing entitlement, the probability of receipt and the ability to estimate with sufficient accuracy the amount receivable. Evidence of entitlement to a legacy exists when the charity has sufficient evidence that a gift has been left to them (through knowledge of the existence of a valid will and the death of the benefactor) and the executor is satisfied that the property in question will not be required to satisfy claims in the estate. Receipt of a legacy must be recognised when it is probable that it will be received and the fair value of the amount receivable, which will generally be the expected cash amount to be distributed to the charity, can be reliably measured.

BRITISH SARCOMA GROUP

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025**

2. Accounting policies (continued)**2.4 Expenditure**

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the charity's objectives, as well as any associated support costs.

2.5 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

2.6 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

2.7 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

2.8 Liabilities

Liabilities are recognised when there is an obligation at the balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

2.9 Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

BRITISH SARCOMA GROUP

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

2. Accounting policies (continued)

2.10 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

3. Income from donations and legacies

	Unrestricted funds 2025 £	Total funds 2025 £	Total funds 2024 £
Donations	298	298	-
Legacies	89,897	89,897	-
	<u>90,195</u>	<u>90,195</u>	<u>-</u>

4. Income from charitable activities

	Unrestricted funds 2025 £	Restricted funds 2025 £	Total funds 2025 £
Delegate Fees	59,149	-	59,149
Exhibitor fees	-	-	-
Sponsorship	-	34,966	34,966
Total 2025	<u>59,149</u>	<u>34,966</u>	<u>94,115</u>

BRITISH SARCOMA GROUP

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025**

4. Income from charitable activities (continued)

	<i>Unrestricted funds 2024 £</i>	<i>Restricted funds 2024 £</i>	<i>Total funds 2024 £</i>
Delegate Fees	60,627	-	60,627
Exhibitor fees	5,355	-	5,355
Sponsorship	-	40,005	40,005
<i>Total 2024</i>	<u>65,982</u>	<u>40,005</u>	<u>105,987</u>

. Sponsorship

	2025 £	2024 £
Immedica Pharma	2,500	1,800
Veriton Pharma	-	5,996
PolyNovo UK Ltd	3,060	2,996
Boehringer Ingelheim Ltd	-	8,995
Takeda UK Ltd	2,995	2,995
DePuy Synthes Spine	-	2,162
Deciphera Pharmaceuticals (UK) Ltd	9,460	10,000
Brainlab Sales GmbH	-	826
Boston Scientific Ltd	-	2,995
Bone Cancer Research Trust	710	1,240
SERB Pharmaceuticals	2,995	-
Proton Partners International	2,995	-
GIST Cancer UK	66	-
Sovereign Medical Ltd	2,995	-
Sarcoma UK	4,690	-
Springworks Therapeutics Inc	2,500	-
	<u>34,966</u>	<u>40,005</u>

BRITISH SARCOMA GROUP

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

5. Investment income

	Unrestricted funds 2025 £	Total funds 2025 £	Total funds 2024 £
Interest received	141	141	-

6. Analysis of expenditure on charitable activities

Summary by fund type

	Unrestricted funds 2025 £	Restricted funds 2025 £	Total 2025 £
Annual conference	61,603	34,966	96,569
Publication of BSG guidelines	6,900	-	6,900
	68,503	34,966	103,469

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £
Annual conference	57,654	40,005	97,659

7. Analysis of expenditure by activities

	Activities undertaken directly 2025 £	Support costs 2025 £	Total funds 2025 £
Annual conference	69,782	26,787	96,569
Publication of BSG guidelines	6,900	-	6,900
	76,682	26,787	103,469

BRITISH SARCOMA GROUP

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

7. Analysis of expenditure by activities (continued)

	<i>Activities undertaken directly 2024 £</i>	<i>Support costs 2024 £</i>	<i>Total funds 2024 £</i>
Annual conference	72,786	24,873	97,659

Analysis of direct costs

	Annual conference 2025 £	Publication of BSG guidelines 2025 £	Total funds 2025 £
Conference costs	49,782	-	49,782
Publication of BSG guidelines	-	6,900	6,900
Secretariat fees	20,000	-	20,000
	69,782	6,900	76,682

	<i>Annual conference 2024 £</i>	<i>Publication of BSG guidelines 2024 £</i>	<i>Total funds 2024 £</i>
Conference costs	52,786	-	52,786
Secretariat fees	20,000	-	20,000
	72,786	-	72,786

BRITISH SARCOMA GROUP

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025**

7. Analysis of expenditure by activities (continued)

Analysis of support costs

	Annual conference 2025 £	Total funds 2025 £
Bank charges	808	808
NSF Membership services and database fee	3,277	3,277
Other support costs	186	186
Irrecoverable VAT	9,416	9,416
Independent examination fees - governance cost	1,665	1,665
Association management	11,428	11,428
Bad debts	7	7
	26,787	26,787

	<i>Annual conference 2024 £</i>	<i>Total funds 2024 £</i>
Bank charges	902	902
NSF Membership services and database fee	3,177	3,177
Other support costs	363	363
Irrecoverable VAT	7,817	7,817
Independent examination fees - governance cost	1,585	1,585
Association management	11,029	11,029
	24,873	24,873

8. Independent examiner's remuneration

	2025 £	2024 £
Fees payable to the charity's independent examiner for the preparation and independent examination of the charity's annual accounts	1,665	1,585

BRITISH SARCOMA GROUP

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025**

9. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2024 - £NIL).

During the year ended 31 March 2025, travelling expenses totalling £Nil (2024: £218) were reimbursed to one Trustee. Additionally reimbursed expenses of £1,113 were incurred for the Trustees' meal during the conference.

10. Debtors

	2025 £	2024 £
Due within one year		
Trade debtors	(30)	12,650
Other debtors	3,582	1,315
	<u>3,552</u>	<u>13,965</u>

11. Creditors: Amounts falling due within one year

	2025 £	2024 £
Trade creditors	30,862	79,842
Other taxation and social security	-	8
Accruals and deferred income	1,665	1,600
	<u>32,527</u>	<u>81,450</u>

12. Financial instruments

	2025 £	2024 £
Financial assets		
Financial assets measured at fair value through income and expenditure	<u>219,196</u>	<u>176,724</u>

Financial assets measured at fair value through income and expenditure comprise bank balances.

BRITISH SARCOMA GROUP

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

13. Statement of funds

Statement of funds - current year

	Balance at 1 April 2024 £	Income £	Expenditure £	Balance at 31 March 2025 £
Unrestricted funds				
General Funds	109,239	149,485	(68,503)	190,221
Restricted funds				
Restricted Fund	-	34,966	(34,966)	-
Total of funds	109,239	184,451	(103,469)	190,221

Statement of funds - prior year

	Balance at 1 April 2023 £	Income £	Expenditure £	Balance at 31 March 2024 £
Unrestricted funds				
General Funds	100,911	65,982	(57,654)	109,239
Restricted funds				
Restricted Fund	-	40,005	(40,005)	-
Total of funds	100,911	105,987	(97,659)	109,239

BRITISH SARCOMA GROUP

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

14. Analysis of net assets between funds

Analysis of net assets between funds - current year

	Unrestricted funds 2025 £	Total funds 2025 £
Current assets	222,748	222,748
Creditors due within one year	(32,527)	(32,527)
Total	190,221	190,221

Analysis of net assets between funds - prior year

	Unrestricted funds 2024 £	Total funds 2024 £
Current assets	190,689	190,689
Creditors due within one year	(81,450)	(81,450)
Total	109,239	109,239

15. Related party transactions

Several Trustees attended the annual conference in the year and paid the appropriate attendance fee at the same rate as other delegates. There were no other related party transactions during the year.

Accounts

BRITISH SARCOMA GROUP

UNAUDITED

TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2024

BRITISH SARCOMA GROUP

CONTENTS

	Page
Reference and administrative details of the charity, its Trustees and advisers	1 - 2
Trustees' report	3 - 6
Independent examiner's report	7
Statement of financial activities	8
Balance sheet	9
Notes to the financial statements	10 - 18

BRITISH SARCOMA GROUP

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS
FOR THE YEAR ENDED 31 MARCH 2024**

Trustees

Dr A Dangoor, President
Ms S E Alsousou (appointed 20 May 2024)
Ms D L Artis
Dr C Benson (appointed 20 May 2024)
Mr P Cool (resigned 26 February 2024)
Mr A Desai
Dr I Fragkandrea-Nixon
Dr S Furtado
Mr C Gerrand
Mr A Hayes
Dr A T J Lee (appointed 20 May 2024)
Ms A Z McCarthy (resigned 26 February 2024)
Ms C A Millman
Mrs A Pabla (resigned 26 February 2024)
Mr O Tilsley
Mr J Vass (appointed 20 May 2024)

Charity registered number

1154928

Principal office

Unit 14 The Stottie Shed
Baker's Yard
Christon Road
Newcastle upon Tyne
NE3 1XD

Secretary

Echo Events & Association Management

Accountants

Kinnair Associates Limited
Chartered Accountants
Aston House
Redburn Road
Newcastle upon Tyne
NE5 1NB

BRITISH SARCOMA GROUP

REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS
(CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2024

Bankers

Lloyds Bank Plc
Ariel House
2138 Coventry Road
Sheldon
Birmingham
B26 3JW

BRITISH SARCOMA GROUP

TRUSTEES' REPORT FOR THE YEAR ENDED 31 MARCH 2024

The Trustees present their annual report together with the financial statements of the charity for the year from 1 April 2023 to 31 March 2024.

The financial statements have been prepared in accordance with the accounting policies set out in the notes to the financial statements and comply with the charity's governing document, the Charities Act 2011 and the relevant version of the Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

Objectives and activities

● Policies and objectives

In setting objectives and planning for activities, the Trustees have given due consideration to general guidance published by the charity commission relating to public benefit.

The objectives of the British Sarcoma Group are: -

1. the relief of sickness by maintaining and advancing the education of medical, nursing and healthcare professionals in the United Kingdom concerned with the treatment and care of patients with bone and soft tissue sarcomas, through the provision of information, training and the identification of best practice;
2. the relief of sickness by the promotion of excellence in the healthcare and the treatment of patients with bone and soft tissue sarcoma, through enabling treatment specialists to identify and share best practice;
3. the relief of sickness and the preservation of health in particular by promoting and supporting research with the publication of the useful results thereof and the development of more effective treatment and care for patients with bone and soft tissue sarcomas; and
4. to advance the education of the medical profession and the general public in all areas relating to sarcoma.

● Main activities undertaken to further the charity's purposes for the public benefit

Providing information about best practice in sarcoma treatment via the website, email updates, reports and other publications.

Running a programme of training and educational events (conferences, workshops, study days) to identify and share best practice.

Running scientific meetings.

Developing and promoting nationally-recognised and adopted clinical guidelines and service standards for the management of sarcoma.

Providing expert representation on sarcoma to the NHS through written responses and membership of advisory groups.

Developing projects to improve sarcoma healthcare and treatment.

Informing medical professionals about new research; promoting opportunities for research; commissioning research into best practice.

BRITISH SARCOMA GROUP

**TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2024**

Objectives and activities (continued)

Providing information and training to generalist medical professionals about sarcoma.

Working with other professional bodies and Royal Colleges to develop joint educational initiatives.

Working with national sarcoma patient organisations to raise awareness of sarcoma amongst public.

Achievements and performance**● Review of activities**

This year the BSG successfully updated and published the following guidelines in the British Journal of Cancer-

- UK BSG Guidelines for the Management of Soft Tissue Sarcomas – 2024 Update
- UK Guidelines for the Management of Gastrointestinal Stromal Tumour (GIST) – 2024 Update
- UK BSG Guidelines for the Management of Bone Sarcomas – 2024 Update

We also completed and published updated Rehabilitation Guidelines to the Journal of Disability & Rehabilitation.

Aside from this we held our annual conference on the 27th & 28th February 2024 at the Royal Armouries, Leeds. The conference attracted a multidisciplinary group of around 300 sarcoma specialists from across the country with a programme featuring over 60 speakers as well as academic poster displays and exhibition. The exhibition attracts leading pharmaceutical and medical providers for the industry.

The Sarcoma SAG (Specialist Advisory Group) held a number of meetings through out the year both virtually and in person. These meetings are facilitated and supported by the BSG and bring SAG chairs together from across the country to share in updates and best practice. BSG members were also involved in work alongside charity partner Sarcoma UK to try and improve the early diagnosis of sarcoma.

Financial review**● Overview**

Income for the year totalled £105,987. The Statement of Financial Activities shows that the main source of income is sponsorship and delegate fees from the annual conference.

Delegate fees are shown under the general fund as unrestricted funds. Total delegate fees for the year were £60,627 (57% of total income).

Sponsorship income is restricted at the request of the donor. Total sponsorship for the year was £40,005 (38% of total income). A full breakdown of sponsors is given in the notes to the financial statements.

Expenditure for the year totalled £97,659 with the main item of charitable expenditure being in relation to the annual conference.

An operating surplus of £8,328 (previous year: deficit of £3,566) was made this year and increases the total general unrestricted funds of the charity at 31 March 2024 to £109,239 (previous period: £100,911).

BRITISH SARCOMA GROUP

**TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2024**

● Going concern

After making appropriate enquiries, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. For this reason, they continue to adopt the going concern basis in preparing the financial statements. Further details regarding the adoption of the going concern basis can be found in the Accounting Policies.

● Reserves policy

The total funds of the charity at 31 March 2024 were £109,239.

The Board of Trustees have agreed it is necessary to maintain a level of reserves to cover the administration costs and 50% of the cost of staging the annual conference. This averages approximately £70,000 in total. The Trustees are pleased to note that the total funds exceed this figure and have plans to use these as explained in the future developments section of this Report.

Structure, governance and management**● Constitution**

The British Sarcoma Group (BSG) is a Charitable Incorporated Organisation (CIO) registered in England and Wales with the Charity Commission on 8 December 2013 with registration number 1154928. Its governing document is its constitution, adopted on 22 May 2013.

● Methods of appointment or election of Trustees

Trustees are appointed by the existing Trustees for a three-year term which is extendable by mutual agreement of other Trustees with a maximum extension of a further three years. This is dependent on the skill set offered by the board member and the need to retain a wide range of key skills relevant to the continued success of the charity. New Trustees receive the BSG constitution, published financial statements, minutes of previous Board of Trustee meetings, as well as the Charity Commission guidance on effective governance.

Trustees meet, on average, three times a year in person or by teleconference.

● Organisational structure and decision-making policies

The day-to-day administration of the British Sarcoma Group and BSG conference management is delivered by Echo AM Limited.

● Financial risk management

The Trustees have assessed the major risks to which the charity is exposed, in particular those related to the operations and finances of the charity, and are satisfied that systems and procedures are in place to mitigate exposure to the major risks.

BRITISH SARCOMA GROUP

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2024

Plans for future periods

In 2024/2025 we will be hosting our annual conference on the 5th & 6th March 2025 at the Hilton Newcastle Gateshead. This event continues to be the principle UK forum for multidisciplinary education in sarcoma. We will be reviewing options for offering educational grants or awards to members, and continuing to host regular SAG meetings which are an important platform for the dissemination and sharing of information. We will also continue to work with other charity partners to improve early diagnosis and treatment of patients with sarcoma.

Statement of Trustees' responsibilities

The Trustees are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charity's transactions and disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the Trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the members of the board of Trustees on 2 December 2024 and signed on their behalf by:

DocuSigned by:

F9792EEC5972467...

Dr A Dangoor
President

BRITISH SARCOMA GROUP

**INDEPENDENT EXAMINER'S REPORT
FOR THE YEAR ENDED 31 MARCH 2024**

Independent examiner's report to the Trustees of British Sarcoma Group ('the charity')

We report to the charity Trustees on our examination of the accounts of the charity for the year ended 31 March 2024.

Responsibilities and basis of report

As the Trustees of the charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').

We report in respect of our examination of the charity's accounts carried out under section 145 of the 2011 Act and in carrying out our examination we have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

Your attention is drawn to the fact that the charity has prepared the financial statements in accordance with the relevant version of the Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). This is in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has been withdrawn.

We understand that this has been done in order for the accounts to provide a true and fair view in accordance with the Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2019.

We have completed our examination. We confirm that no matters have come to our attention in connection with the examination giving us cause to believe that in any material respect:


1. accounting records were not kept in respect of the charity as required by section 130 of the 2011 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

We have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

This report is made solely to the charity's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our work has been undertaken so that we might state to the charity's Trustees those matters we are required to state to them in an Independent examiner's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's Trustees as a body, for our work or for this report.

Signed:

DocuSigned by:



Dated: 13 January 2025

Detlev Anderson FCA

8228AFA7794A4DC...

Kinnair Associates Limited
Chartered Accountants
Aston House
Redburn Road
Newcastle upon Tyne
NE5 1NB

BRITISH SARCOMA GROUP

STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 MARCH 2024

	Note	Unrestricted funds 2024 £	Restricted funds 2024 £	Total funds 2024 £	Total funds 2023 £
Income from:					
Charitable activities	3	65,982	40,005	105,987	107,130
Total income		65,982	40,005	105,987	107,130
Expenditure on:					
Charitable activities	4	57,654	40,005	97,659	110,696
Total expenditure		57,654	40,005	97,659	110,696
Net movement in funds		8,328	-	8,328	(3,566)
Reconciliation of funds:					
Total funds brought forward		100,911	-	100,911	104,477
Net movement in funds		8,328	-	8,328	(3,566)
Total funds carried forward		109,239	-	109,239	100,911

The Statement of financial activities includes all gains and losses recognised in the year.

The notes on pages 10 to 18 form part of these financial statements.

BRITISH SARCOMA GROUP

BALANCE SHEET
AS AT 31 MARCH 2024

	Note	2024 £	2023 £
Current assets			
Debtors	8	13,965	8,015
Cash at bank and in hand		176,724	122,901
		<u>190,689</u>	<u>130,916</u>
Creditors: amounts falling due within one year	9	(81,450)	(30,005)
Net current assets		<u>109,239</u>	<u>100,911</u>
Total assets less current liabilities		<u>109,239</u>	<u>100,911</u>
Total net assets		<u>109,239</u>	<u>100,911</u>
Charity funds			
Restricted funds	11	-	-
Unrestricted funds	11	109,239	100,911
Total funds		<u>109,239</u>	<u>100,911</u>

The financial statements were approved and authorised for issue by the Trustees on 02 December 2024 and signed on their behalf by:

DocuSigned by:

F9792EEC5972467...

Dr A Dangoor
President

The notes on pages 10 to 18 form part of these financial statements.

BRITISH SARCOMA GROUP

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024**

1. General information

British Sarcoma Group is a charitable incorporated organisation, charity number 1154928. The registered office is Unit 14, The Stottie Shed, Baker's Yard, Christon Road, Newcastle upon Tyne, NE3 1XD.

2. Accounting policies**2.1 Basis of preparation of financial statements**

The financial statements have been prepared in accordance with the relevant version of the Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011 and UK Generally Accepted Accounting Practice.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair view'. This departure has involved following the relevant version of the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

British Sarcoma Group meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The financial statements are prepared in pounds Sterling and rounded to the nearest pound.

2.2 Going concern

The charity has cash resources and no requirement for external funding. The Trustees have reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. They continue to believe the going concern basis of accounting is appropriate in preparing the annual financial statements.

2.3 Income

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

2.4 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the charity's objectives, as well as any associated support costs.

BRITISH SARCOMA GROUP

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024**

2. Accounting policies (continued)**2.5 Debtors**

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

2.6 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

2.7 Liabilities

Liabilities are recognised when there is an obligation at the balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

2.8 Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

2.9 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

BRITISH SARCOMA GROUP

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

3. Income from charitable activities

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total funds 2024 £
Delegate Fees	60,627	-	60,627
Exhibitor fees	5,355	-	5,355
Sponsorship	-	40,005	40,005
Total 2024	65,982	40,005	105,987

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total funds 2023 £
Delegate Fees	55,660	-	55,660
Exhibitor fees	5,100	-	5,100
Sponsorship	-	45,870	45,870
Delegate bag inserts	-	500	500
<i>Total 2023</i>	<i>60,760</i>	<i>46,370</i>	<i>107,130</i>

BRITISH SARCOMA GROUP

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024**

Sponsorship

	2024	<i>2023</i>
	£	<i>£</i>
Immedica Pharma	1,800	<i>2,500</i>
Veriton Pharma	5,996	<i>-</i>
PolyNovo UK Ltd	2,996	<i>2,500</i>
Boehringer Ingelheim Ltd	8,995	<i>10,495</i>
Takeda UK Ltd	2,995	<i>2,995</i>
DePuy Synthes Spine	2,162	<i>-</i>
Deciphera Pharmaceuticals (UK) Ltd	10,000	<i>-</i>
Brainlab Sales GmbH	826	<i>-</i>
Boston Scientific Ltd	2,995	<i>2,995</i>
Bone Cancer Research Trust	1,240	<i>-</i>
Bayer Plc	-	<i>14,995</i>
IGEA Medical	-	<i>2,995</i>
Cognite Communications Ltd	-	<i>6,395</i>
	40,005	<i>45,870</i>

4. Analysis of expenditure on charitable activities
Summary by fund type

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £
Annual conference	57,654	40,005	97,659
	<i>Unrestricted funds 2023 £</i>	<i>Restricted funds 2023 £</i>	<i>Total 2023 £</i>
Annual conference	<i>64,326</i>	<i>46,370</i>	<i>110,696</i>

BRITISH SARCOMA GROUP

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

5. Analysis of expenditure by activities

	Activities undertaken directly 2024 £	Support costs 2024 £	Total funds 2024 £
Annual conference	72,786	24,873	97,659

	Activities undertaken directly 2023 £	Support costs 2023 £	Total funds 2023 £
Annual conference	85,909	24,787	110,696

Analysis of direct costs

	Annual conference 2024 £	Total funds 2024 £
Conference costs	52,786	52,786
Secretariat fees	20,000	20,000
	72,786	72,786

	Annual conference 2023 £	Total funds 2023 £
Conference costs	65,909	65,909
Secretariat fees	20,000	20,000
	85,909	85,909

BRITISH SARCOMA GROUP

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024**

5. Analysis of expenditure by activities (continued)

Analysis of support costs

	Annual conference 2024 £	Total funds 2024 £
Bank charges	902	902
NSF Membership services and database fee	3,177	3,177
Other support costs	363	363
Irrecoverable VAT	7,817	7,817
Independent examination fees - governance cost	1,585	1,585
Association management	11,029	11,029
	24,873	24,873

	<i>Annual conference 2023 £</i>	<i>Total funds 2023 £</i>
Bank charges	750	750
NSF Membership services and database fee	2,977	2,977
Other support costs	1,441	1,441
Irrecoverable VAT	7,989	7,989
Independent examination fees - governance cost	1,400	1,400
Association management	10,230	10,230
	24,787	24,787

6. Independent examiner's remuneration

	2024 £	<i>2023 £</i>
Fees payable to the charity's independent examiner for the preparation and independent examination of the charity's annual accounts	1,585	1,400

BRITISH SARCOMA GROUP

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024**

7. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2023 - £NIL).

During the year ended 31 March 2024, travelling expenses totalling £218 (2023: £nil) were reimbursed to one Trustee.

8. Debtors

	2024 £	2023 £
Due within one year		
Trade debtors	12,650	2,414
Other debtors	1,315	5,601
	<u>13,965</u>	<u>8,015</u>

9. Creditors: Amounts falling due within one year

	2024 £	2023 £
Trade creditors	79,842	26,394
Other taxation and social security	8	-
Other creditors	-	356
Accruals and deferred income	1,600	3,255
	<u>81,450</u>	<u>30,005</u>

10. Financial instruments

	2024 £	2023 £
Financial assets		
Financial assets measured at fair value through income and expenditure	<u>176,724</u>	<u>122,901</u>

Financial assets measured at fair value through income and expenditure comprise bank balances.

BRITISH SARCOMA GROUP

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

11. Statement of funds

Statement of funds - current year

	Balance at 1 April 2023 £	Income £	Expenditure £	Balance at 31 March 2024 £
Unrestricted funds				
General Funds	100,911	65,982	(57,654)	109,239
Restricted funds				
Restricted Fund	-	40,005	(40,005)	-
Total of funds	100,911	105,987	(97,659)	109,239

Statement of funds - prior year

	Balance at 1 April 2022 £	Income £	Expenditure £	Balance at 31 March 2023 £
Unrestricted funds				
General Funds	104,477	60,760	(64,326)	100,911
Restricted funds				
Restricted Fund	-	46,370	(46,370)	-
Total of funds	104,477	107,130	(110,696)	100,911

BRITISH SARCOMA GROUP

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

12. Analysis of net assets between funds

Analysis of net assets between funds - current period

	Unrestricted funds 2024 £	Total funds 2024 £
Current assets	190,689	190,689
Creditors due within one year	(81,450)	(81,450)
Total	109,239	109,239

Analysis of net assets between funds - prior period

	Unrestricted funds 2023 £	Total funds 2023 £
Current assets	130,916	130,916
Creditors due within one year	(30,005)	(30,005)
Total	100,911	100,911

13. Related party transactions

Several Trustees attended the annual conference in the year and paid the appropriate attendance fee at the same rate as other delegates. There were no other related party transactions during the year.

Accounts

BRITISH SARCOMA GROUP

UNAUDITED

TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2023

BRITISH SARCOMA GROUP

CONTENTS

	Page
Reference and administrative details of the charity, its Trustees and advisers	1
Trustees' report	2 - 5
Independent examiner's report	6
Statement of financial activities	7
Balance sheet	8
Notes to the financial statements	9 - 17

BRITISH SARCOMA GROUP

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS
FOR THE YEAR ENDED 31 MARCH 2023**

Trustees

Mr P Cool
Dr A Dangoor, President
Mr A Desai
Dr I Fragkandrea-Nixon
Dr S Furtado (appointed 6 June 2022)
Mr C Gerrand
Mr A Hayes
Ms A Z McCarthy
Ms C A Millman (appointed 6 June 2022)
Mrs A Pabla
Dr B Seddon (resigned 5 September 2022)
Mr O Tilsley
Ms D L Artis (appointed 12 December 2022)

Charity registered number

1154928

Principal office

Unit 14 The Stottie Shed
Baker's Yard
Christon Road
Newcastle upon Tyne
NE3 1XD

Secretary

Echo Events & Association Management

Accountants

Kinnair Associates Limited
Chartered Accountants
Aston House
Redburn Road
Newcastle upon Tyne
NE5 1NB

Bankers

Lloyds Bank Plc
Ariel House
2138 Coventry Road
Sheldon
Birmingham
B26 3JW

BRITISH SARCOMA GROUP

**TRUSTEES' REPORT
FOR THE YEAR ENDED 31 MARCH 2023**

The Trustees present their annual report together with the financial statements of the charity for the year from 1 April 2022 to 31 March 2023.

The financial statements have been prepared in accordance with the accounting policies set out in the notes to the financial statements and comply with the charity's governing document, the Charities Act 2011 and the relevant version of the Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

Objectives and activities**● Policies and objectives**

In setting objectives and planning for activities, the Trustees have given due consideration to general guidance published by the charity commission relating to public benefit.

The objectives of the British Sarcoma Group are: -

1. the relief of sickness by maintaining and advancing the education of medical, nursing and healthcare professionals in the United Kingdom concerned with the treatment and care of patients with bone and soft tissue sarcomas, through the provision of information, training and the identification of best practice;
2. the relief of sickness by the promotion of excellence in the healthcare and the treatment of patients with bone and soft tissue sarcoma, through enabling treatment specialists to identify and share best practice;
3. the relief of sickness and the preservation of health in particular by promoting and supporting research with the publication of the useful results thereof and the development of more effective treatment and care for patients with bone and soft tissue sarcomas; and
4. to advance the education of the medical profession and the general public in all areas relating to sarcoma.

● Main activities undertaken to further the charity's purposes for the public benefit

Providing information about best practice in sarcoma treatment via the website, email updates, reports and other publications.

Running a programme of training and educational events (conferences, workshops, study days) to identify and share best practice.

Running scientific meetings.

Developing and promoting nationally-recognised and adopted clinical guidelines and service standards for the management of sarcoma.

Providing expert representation on sarcoma to the NHS through written responses and membership of advisory groups.

Developing projects to improve sarcoma healthcare and treatment.

Informing medical professionals about new research; promoting opportunities for research; commissioning research into best practice.

BRITISH SARCOMA GROUP

**TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2023**

Objectives and activities (continued)

Providing information and training to generalist medical professionals about sarcoma.

Working with other professional bodies and Royal Colleges to develop joint educational initiatives.

Working with national sarcoma patient organisations to raise awareness of sarcoma amongst public.

Achievements and performance**● Review of activities**

One of our main activities for the year was the BSG Annual conference which took place on the 22nd & 23rd March 2023 at the ICC Wales. The conference is the principle UK forum for multidisciplinary education in sarcoma. The event attracted approximately 300 sarcoma professionals from across the UK and had a programme featuring over 20 speakers as well as academic poster displays and exhibition. The exhibition attracts leading pharmaceutical and medical providers for the industry.

Other work included the finalising of the nationally recognised clinical guidelines for the management of sarcoma looking specifically at Soft Tissue Sarcomas, Bone and GIST. This is a large piece of ongoing work which aims to be finished and published in 2023.

The SAG (Sarcoma Awareness Group) held a number of meetings through out the year both virtually and in face. These meetings are facilitated and supported by the BSG and bring SAG chairs together from across the country to share in updates and best practice.

Financial review**● Overview**

Income for the year totalled £107,130. The Statement of Financial Activities shows that the main source of income is sponsorship and delegate fees from the annual conference.

Delegate fees are shown under the general fund as unrestricted funds. Total delegate fees for the year were £55,660 (52% of total income).

Sponsorship income is restricted at the request of the donor. Total sponsorship for the year was £46,370 (43.3% of total income). A full breakdown of sponsors is given in the notes to the financial statements.

Expenditure for the year totalled £110,696 with the main item of charitable expenditure being in relation to the annual conference.

An operating deficit of £3,566 (previous year: surplus of £1,785) was made this year and decreases the total general unrestricted funds of the charity at 31 March 2023 to £100,911 (previous period: £104,477).

● Going concern

After making appropriate enquiries, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. For this reason, they continue to adopt the going concern basis in preparing the financial statements. Further details regarding the adoption of the going concern basis can be found in the Accounting Policies.

BRITISH SARCOMA GROUP

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2023

● Reserves policy

The total funds of the charity at 31 March 2023 were £100,911.

The Board of Trustees have agreed it is necessary to maintain a level of reserves to cover the administration costs and 50% of the cost of staging the annual conference. This averages approximately £70,000 in total. The Trustees are pleased to note that the total funds exceed this figure and have plans to use these as explained in the future developments section of this Report.

Structure, governance and management

● Constitution

The British Sarcoma Group (BSG) is a Charitable Incorporated Organisation (CIO) registered in England and Wales with the Charity Commission on 8 December 2013 with registration number 1154928. Its governing document is its constitution, adopted on 22 May 2013.

● Methods of appointment or election of Trustees

Trustees are appointed by the existing Trustees for a three-year term which is extendable by mutual agreement of other Trustees with a maximum extension of a further three years. This is dependent on the skill set offered by the board member and the need to retain a wide range of key skills relevant to the continued success of the charity. New Trustees receive the BSG constitution, published financial statements, minutes of previous Board of Trustee meetings, as well as the Charity Commission guidance on effective governance.

Trustees meet, on average, three times a year in person or by teleconference.

● Organisational structure and decision-making policies

The day-to-day administration of the British Sarcoma Group and BSG conference management is delivered by Echo AM Limited.

● Financial risk management

The Trustees have assessed the major risks to which the charity is exposed, in particular those related to the operations and finances of the charity, and are satisfied that systems and procedures are in place to mitigate exposure to the major risks.

Plans for future periods

In 2023/2024 the BSG plans to submit the clinical guidelines on sarcoma management to a reputable medical journal for publication. We will be organising our annual conference on the 27th & 28th February at the Royal Armouries in Leeds. With a mixture of international and national speakers sharing the latest in sarcoma to multidisciplinary teams from all major cancer centres in the UK. We will also be continuing to support with the SAG meetings which are an important platform for the dissemination and sharing of information.

BRITISH SARCOMA GROUP

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2023

Statement of Trustees' responsibilities

The Trustees are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charity's transactions and disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the Trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the members of the board of Trustees on 11 December 2023 and signed on their behalf by:

DocuSigned by:

F9792EEC5972467...

Dr A Dangoor
President

BRITISH SARCOMA GROUP

**INDEPENDENT EXAMINER'S REPORT
FOR THE YEAR ENDED 31 MARCH 2023**

Independent examiner's report to the Trustees of British Sarcoma Group ('the charity')

We report to the charity Trustees on our examination of the accounts of the charity for the year ended 31 March 2023.

Responsibilities and basis of report

As the Trustees of the charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').

We report in respect of our examination of the charity's accounts carried out under section 145 of the 2011 Act and in carrying out our examination we have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

Your attention is drawn to the fact that the charity has prepared the financial statements in accordance with the relevant version of the Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). This is in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has been withdrawn.


We understand that this has been done in order for the accounts to provide a true and fair view in accordance with the Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2019.

We have completed our examination. We confirm that no matters have come to our attention in connection with the examination giving us cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 130 of the 2011 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

We have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

This report is made solely to the charity's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our work has been undertaken so that we might state to the charity's Trustees those matters we are required to state to them in an Independent examiner's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's Trustees as a body, for our work or for this report.

Signed: 
Detlev Anderson FCA

Dated: 25 January 2024

Kinnair Associates Limited
Chartered Accountants
Aston House
Redburn Road
Newcastle upon Tyne
NE5 1NB

BRITISH SARCOMA GROUP

STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 MARCH 2023

	Note	Unrestricted funds 2023 £	Restricted funds 2023 £	Total funds 2023 £	Total funds 2022 £
Income from:					
Charitable activities	3	60,760	46,370	107,130	101,195
Total income		60,760	46,370	107,130	101,195
Expenditure on:					
Charitable activities	4	64,326	46,370	110,696	99,410
Total expenditure		64,326	46,370	110,696	99,410
Net movement in funds		(3,566)	-	(3,566)	1,785
Reconciliation of funds:					
Total funds brought forward		104,477	-	104,477	102,692
Net movement in funds		(3,566)	-	(3,566)	1,785
Total funds carried forward		100,911	-	100,911	104,477

The Statement of financial activities includes all gains and losses recognised in the year.

The notes on pages 9 to 17 form part of these financial statements.

BRITISH SARCOMA GROUP

BALANCE SHEET
AS AT 31 MARCH 2023

	Note	2023 £	2022 £
Current assets			
Debtors	8	8,015	7,882
Cash at bank and in hand		122,901	143,518
		<u>130,916</u>	<u>151,400</u>
Creditors: amounts falling due within one year	9	(30,005)	(46,923)
Net current assets		<u>100,911</u>	<u>104,477</u>
Total assets less current liabilities		<u>100,911</u>	<u>104,477</u>
Total net assets		<u>100,911</u>	<u>104,477</u>
Charity funds			
Restricted funds	11	-	-
Unrestricted funds	11	100,911	104,477
Total funds		<u>100,911</u>	<u>104,477</u>

The financial statements were approved and authorised for issue by the Trustees on 11 December 2023 and signed on their behalf by:

DocuSigned by:

 F9792EEC5972467...

Dr A Dangoor
 President

The notes on pages 9 to 17 form part of these financial statements.

BRITISH SARCOMA GROUP

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023**

1. General information

British Sarcoma Group is a charitable incorporated organisation, charity number 1154928. The registered office is Unit 14, The Stottie Shed, Baker's Yard, Christon Road, Newcastle upon Tyne, NE3 1XD.

2. Accounting policies**2.1 Basis of preparation of financial statements**

The financial statements have been prepared in accordance with the relevant version of the Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011 and UK Generally Accepted Accounting Practice.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair view'. This departure has involved following the relevant version of the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

British Sarcoma Group meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

2.2 Going concern

The charity has cash resources and no requirement for external funding. The Trustees have reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. They continue to believe the going concern basis of accounting is appropriate in preparing the annual financial statements.

2.3 Income

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

2.4 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the charity's objectives, as well as any associated support costs.

BRITISH SARCOMA GROUP

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023**

2. Accounting policies (continued)**2.5 Debtors**

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

2.6 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

2.7 Liabilities

Liabilities are recognised when there is an obligation at the balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

2.8 Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

2.9 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

BRITISH SARCOMA GROUP

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023**

3. Income from charitable activities

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total funds 2023 £
Delegate Fees	55,660	-	55,660
Exhibitor fees	5,100	-	5,100
Sponsorship - Immedica Pharma	-	2,500	2,500
Sponsorship - PolyNovo UK Limited	-	2,500	2,500
Sponsorship - Bayer Plc	-	14,995	14,995
Sponsorship - Takeda UK Ltd	-	2,995	2,995
Sponsorship - Blueprint Medicines	-	-	-
Sponsorship - Cognite Communications Limited	-	6,395	6,395
Sponsorship - Boehringer Ingelheim Limited	-	10,495	10,495
Sponsorship - Stryker European Operations Ltd	-	-	-
Sponsorship - Boston Scientific Ltd	-	2,995	2,995
Sponsorship - IGEA Medical	-	2,995	2,995
Sponsorship - Delegate bag inserts	-	500	500
Total 2023	60,760	46,370	107,130

	Unrestricted funds 2022 £	Restricted funds 2022 £	Total funds 2022 £
Delegate Fees	59,020	-	59,020
Exhibitor fees	2,968	-	2,968
Sponsorship - Immedica Pharma	-	14,995	14,995
Sponsorship - PolyNovo UK Limited	-	2,247	2,247
Sponsorship - Bayer Plc	-	8,500	8,500
Sponsorship - Takeda UK Ltd	-	5,995	5,995
Sponsorship - Stryker European Operations Ltd	-	2,500	2,500
Sponsorship - Boston Scientific Ltd	-	2,995	2,995
Sponsorship - IGEA Medical	-	1,975	1,975
Total 2022	61,988	39,207	101,195

BRITISH SARCOMA GROUP

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023**

4. Analysis of expenditure on charitable activities

Summary by fund type

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
Annual conference	64,326	46,370	110,696
	<u>64,326</u>	<u>46,370</u>	<u>110,696</u>
	<i>Unrestricted funds 2022 £</i>	<i>Restricted funds 2022 £</i>	<i>Total 2022 £</i>
Annual conference	60,203	39,207	99,410
	<u>60,203</u>	<u>39,207</u>	<u>99,410</u>

5. Analysis of expenditure by activities

	Activities undertaken directly 2023 £	Support costs 2023 £	Total funds 2023 £
Annual conference	85,909	24,787	110,696
	<u>85,909</u>	<u>24,787</u>	<u>110,696</u>
	<i>Activities undertaken directly 2022 £</i>	<i>Support costs 2022 £</i>	<i>Total funds 2022 £</i>
Annual conference	74,282	25,128	99,410
	<u>74,282</u>	<u>25,128</u>	<u>99,410</u>

BRITISH SARCOMA GROUP

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023**

5. Analysis of expenditure by activities (continued)

Analysis of direct costs

	Annual conference 2023 £	Total funds 2023 £
Conference costs	65,909	65,909
Secretariat fees	20,000	20,000
	85,909	85,909

	<i>Annual conference 2022 £</i>	<i>Total funds 2022 £</i>
Conference costs	54,282	54,282
Secretariat fees	20,000	20,000
	74,282	74,282

Analysis of support costs

	Annual conference 2023 £	Total funds 2023 £
Bank charges	750	750
NSF Membership services and database fee	2,977	2,977
Other support costs	1,441	1,441
Irrecoverable VAT	7,989	7,989
Independent examination fees - governance cost	1,400	1,400
Association management	10,230	10,230
	24,787	24,787

BRITISH SARCOMA GROUP

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023**

5. Analysis of expenditure by activities (continued)

Analysis of support costs (continued)

	<i>Annual conference 2022 £</i>	<i>Total funds 2022 £</i>
Bank charges	813	813
NSF Membership services and database fee	2,920	2,920
Other support costs	1,596	1,596
Irrecoverable VAT	8,234	8,234
Independent examination fees - governance cost	1,565	1,565
Association management	10,000	10,000
	<u>25,128</u>	<u>25,128</u>

6. Independent examiner's remuneration

	2023 £	2022 £
Fees payable to the charity's independent examiner for the preparation and independent examination of the charity's annual accounts	<u>1,400</u>	<u>1,330</u>

7. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2022 - £NIL).

During the year ended 31 March 2023, no expenses were reimbursed or paid directly to Trustees (2022 - £707 reimbursed to one Trustee which related to cost of board meal).

8. Debtors

	2023 £	2022 £
Due within one year		
Trade debtors	2,414	7,629
Other debtors	5,601	253
	<u>8,015</u>	<u>7,882</u>

BRITISH SARCOMA GROUP

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023**

9. Creditors: Amounts falling due within one year

	2023	<i>2022</i>
	£	<i>£</i>
Trade creditors	26,394	<i>44,404</i>
Other taxation and social security	-	<i>474</i>
Other creditors	356	<i>-</i>
Accruals and deferred income	3,255	<i>2,045</i>
	<u>30,005</u>	<i><u>46,923</u></i>

10. Financial instruments

	2023	<i>2022</i>
	£	<i>£</i>
Financial assets		
Financial assets measured at fair value through income and expenditure	<u>122,901</u>	<i><u>143,518</u></i>

Financial assets measured at fair value through income and expenditure comprise bank balances.

BRITISH SARCOMA GROUP

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023

11. Statement of funds

Statement of funds - current year

	Balance at 1 April 2022 £	Income £	Expenditure £	Balance at 31 March 2023 £
Unrestricted funds				
General Funds	104,477	60,760	(64,326)	100,911
Restricted funds				
Restricted Fund	-	46,370	(46,370)	-
Total of funds	104,477	107,130	(110,696)	100,911

Statement of funds - prior year

	Balance at 1 April 2021 £	Income £	Expenditure £	Balance at 31 March 2022 £
Unrestricted funds				
General Funds	102,692	61,988	(60,203)	104,477
Restricted funds				
Restricted Fund	-	39,207	(39,207)	-
Total of funds	102,692	101,195	(99,410)	104,477

BRITISH SARCOMA GROUP

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023**

12. Analysis of net assets between funds

Analysis of net assets between funds - current year

	Unrestricted funds 2023 £	Total funds 2023 £
Current assets	130,916	130,916
Creditors due within one year	(30,005)	(30,005)
Total	<u>100,911</u>	<u>100,911</u>

Analysis of net assets between funds - prior year

	<i>Unrestricted funds 2022 £</i>	<i>Total funds 2022 £</i>
Current assets	151,400	151,400
Creditors due within one year	(46,923)	(46,923)
Total	<u>104,477</u>	<u>104,477</u>

13. Related party transactions

Several trustees attended the annual conference in the year and paid the appropriate attendance fee at the same rate as other delegates. There were no other related party transactions during the year.

Accounts

BRITISH SARCOMA GROUP

UNAUDITED

TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2022

BRITISH SARCOMA GROUP

CONTENTS

	Page
Reference and administrative details of the charity, its Trustees and advisers	1
Trustees' report	2 - 5
Independent examiner's report	6
Statement of financial activities	7
Balance sheet	8
Notes to the financial statements	9 - 17

BRITISH SARCOMA GROUP

REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 MARCH 2022

Trustees

Mr P Cool
Dr A Dangoor, President
Mr A Desai (appointed 22 March 2022)
Dr I Fragkandrea-Nixon
Dr S Furtado (appointed 6 June 2022)
Mr C Gerrand
Mr A Hayes
Professor I Judson (resigned 13 December 2021)
Ms A Z McCarthy
Ms C A Millman (appointed 6 June 2022)
Mrs A Pabla
Dr B Seddon (resigned 5 September 2022)
Mr O Tilsley

Charity registered number

1154928

Principal office

Unit 14 The Stottie Shed
Baker's Yard
Christon Road
Newcastle upon Tyne
NE3 1XD

Secretary

Echo Events & Association Management

Accountants

Kinnair Associates Limited
Chartered Accountants
Aston House
Redburn Road
Newcastle upon Tyne
NE5 1NB

Bankers

Lloyds Bank Plc
Ariel House
2138 Coventry Road
Sheldon
Birmingham
B26 3JW

BRITISH SARCOMA GROUP

TRUSTEES' REPORT FOR THE YEAR ENDED 31 MARCH 2022

The Trustees present their annual report together with the financial statements of the charity for the year from 1 April 2021 to 31 March 2022.

The financial statements have been prepared in accordance with the accounting policies set out in the notes to the financial statements and comply with the charity's governing document, the Charities Act 2011 and the relevant version of the Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

Objectives and activities

● Policies and objectives

In setting objectives and planning for activities, the Trustees have given due consideration to general guidance published by the charity commission relating to public benefit.

The objectives of the British Sarcoma Group are: -

1. the relief of sickness by maintaining and advancing the education of medical, nursing and healthcare professionals in the United Kingdom concerned with the treatment and care of patients with bone and soft tissue sarcomas, through the provision of information, training and the identification of best practice;
2. the relief of sickness by the promotion of excellence in the healthcare and the treatment of patients with bone and soft tissue sarcoma, through enabling treatment specialists to identify and share best practice;
3. the relief of sickness and the preservation of health in particular by promoting and supporting research with the publication of the useful results thereof and the development of more effective treatment and care for patients with bone and soft tissue sarcomas; and
4. to advance the education of the medical profession and the general public in all areas relating to sarcoma.

● Main activities undertaken to further the charity's purposes for the public benefit

Providing information about best practice in sarcoma treatment via the website, email updates, reports and other publications.

Running a programme of training and educational events (conferences, workshops, study days) to identify and share best practice.

Running scientific meetings.

Developing and promoting nationally-recognised and adopted clinical guidelines and service standards for the management of sarcoma.

Providing expert representation on sarcoma to the NHS through written responses and membership of advisory groups.

Developing projects to improve sarcoma healthcare and treatment.

Informing medical professionals about new research; promoting opportunities for research; commissioning research into best practice.

Providing information and training to generalist medical professionals about sarcoma.

BRITISH SARCOMA GROUP

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2022

Objectives and activities (continued)

Working with other professional bodies and Royal Colleges to develop joint educational initiatives.

Working with national sarcoma patient organisations to raise awareness of sarcoma amongst public.

Achievements and performance

● Review of activities

The main achievements of the BSG in this financial year were to deliver the virtual annual conference, the major UK forum for multidisciplinary education in sarcoma. The Specialty Advisory Group chairs meetings were also supported. The BSG continues to develop nationally recognised clinical guidelines for the management of sarcoma.

Financial review

● Going concern

After making appropriate enquiries, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. This is despite the effects of COVID-19 as delivery of educational workshops are to return to face to face events in the next financial year. For this reason, they continue to adopt the going concern basis in preparing the financial statements. Further details regarding the adoption of the going concern basis can be found in the Accounting Policies.

● Reserves policy

The total funds of the charity at 31 March 2022 were £104,477.

The Board of Trustees have agreed it is necessary to maintain a level of reserves to cover the administration costs and the cost of staging the annual conference. This averages approximately £70,000 in total. The Trustees are pleased to note that the total funds exceed this figure and have plans to use these as explained in the future developments section of this Report.

● Overview

Income for the year totalled £101,195. The Statement of Financial Activities shows that the main source of income is sponsorship and delegate fees from the annual conference.

Delegate fees are shown under the general fund as unrestricted funds. Total delegate fees for the year were £59,020 (58.3% of total income).

Sponsorship income is restricted at the request of the donor. Total sponsorship for the year was £39,207 (38.7% of total income). A full breakdown of sponsors is given in the notes to the financial statements.

Expenditure for the year totalled £99,410 with the main item of charitable expenditure being in relation to the annual conference.

An operating surplus of £1,785 (previous year: deficit of £9,927) was made this year and increases the total general unrestricted funds of the charity at 31 March 2022 to £104,477 (previous period: £102,692).

BRITISH SARCOMA GROUP

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2022

Structure, governance and management

- **Constitution**

The British Sarcoma Group (BSG) is a Charitable Incorporated Organisation (CIO) registered in England and Wales with the Charity Commission on 8 December 2013 with registration number 1154928. Its governing document is its constitution, adopted on 22 May 2013.

- **Methods of appointment or election of Trustees**

Trustees are appointed by the existing Trustees for a three-year term which is extendable by mutual agreement of other Trustees with a maximum extension of a further three years. This is dependent on the skill set offered by the board member and the need to retain a wide range of key skills relevant to the continued success of the charity. New Trustees receive the BSG constitution, published financial statements, minutes of previous Board of Trustee meetings, as well as the Charity Commission guidance on effective governance.

Trustees meet on average three times a year in person or by teleconference.

- **Organisational structure and decision-making policies**

The day-to-day administration of the British Sarcoma Group and BSG conference management is delivered by Echo AM Limited.

- **Financial risk management**

The Trustees have assessed the major risks to which the charity is exposed, in particular those related to the operations and finances of the charity, and are satisfied that systems and procedures are in place to mitigate exposure to the major risks.

Plans for future periods

In addition to the continuing activities referred to earlier in this Report the Trustees plan to spend funds in the 2021/22 year on a return to face to face educational workshops, including the annual conference, as initiatives to bring the sarcoma community together to optimise patient care.

BRITISH SARCOMA GROUP**TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2022****Statement of Trustees' responsibilities**

The Trustees are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charity's transactions and disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the Trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the members of the board of Trustees on 21 December 2022 and signed on their behalf by:

DocuSigned by:

F9792EEC5972467...

Dr A Dangoor
President

BRITISH SARCOMA GROUP**INDEPENDENT EXAMINER'S REPORT
FOR THE YEAR ENDED 31 MARCH 2022****Independent examiner's report to the Trustees of British Sarcoma Group ('the charity')**

We report to the charity Trustees on our examination of the accounts of the charity for the year ended 31 March 2022.

Responsibilities and basis of report

As the Trustees of the charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').

We report in respect of our examination of the charity's accounts carried out under section 145 of the 2011 Act and in carrying out our examination we have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

Your attention is drawn to the fact that the charity has prepared the financial statements in accordance with the relevant version of the Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). This is in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has been withdrawn.


We understand that this has been done in order for the accounts to provide a true and fair view in accordance with the Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2019.

We have completed our examination. We confirm that no matters have come to our attention in connection with the examination giving us cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 130 of the 2011 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

We have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

This report is made solely to the charity's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our work has been undertaken so that we might state to the charity's Trustees those matters we are required to state to them in an Independent examiner's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's Trustees as a body, for our work or for this report.

Signed: 
Detlev Anderson FCA

Dated: 21 December 2022

Kinnair Associates Limited
Chartered Accountants
Aston House
Redburn Road
Newcastle upon Tyne
NE5 1NB

BRITISH SARCOMA GROUP

STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 MARCH 2022

	Note	Unrestricted funds 2022 £	Restricted funds 2022 £	Total funds 2022 £	Total funds 2021 £
Income from:					
Charitable activities	3	61,988	39,207	101,195	32,250
Total income		61,988	39,207	101,195	32,250
Expenditure on:					
Charitable activities	5	60,203	39,207	99,410	42,177
Total expenditure		60,203	39,207	99,410	42,177
Net movement in funds		1,785	-	1,785	(9,927)
Reconciliation of funds:					
Total funds brought forward		102,692	-	102,692	112,619
Net movement in funds		1,785	-	1,785	(9,927)
Total funds carried forward		104,477	-	104,477	102,692

The Statement of financial activities includes all gains and losses recognised in the year.

The notes on pages 9 to 17 form part of these financial statements.

BRITISH SARCOMA GROUP

BALANCE SHEET
AS AT 31 MARCH 2022

	Note	2022 £	2021 £
Current assets			
Debtors	9	7,882	3,615
Cash at bank and in hand		143,518	103,432
		<u>151,400</u>	<u>107,047</u>
Creditors: amounts falling due within one year	10	(46,923)	(4,355)
Net current assets		<u>104,477</u>	<u>102,692</u>
Total assets less current liabilities		<u>104,477</u>	<u>102,692</u>
Total net assets		<u>104,477</u>	<u>102,692</u>
Charity funds			
Restricted funds	12	-	-
Unrestricted funds	12	104,477	102,692
Total funds		<u>104,477</u>	<u>102,692</u>

The financial statements were approved and authorised for issue by the Trustees on 21 December 2022 and signed on their behalf by:

DocuSigned by:

 F9792EEC5972467...

Dr A Dangoor
 President

The notes on pages 9 to 17 form part of these financial statements.

BRITISH SARCOMA GROUP

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2022

1. General information

British Sarcoma Group is a charitable entity, charity number 1154928. The registered office is Unit 14, The Stottie Shed, Baker's Yard, Christon Road, Newcastle upon Tyne, NE3 1XD.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the relevant version of the Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011 and UK Generally Accepted Accounting Practice.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair view'. This departure has involved following the relevant version of the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

British Sarcoma Group meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

2.2 Going concern

The charity has cash resources and no requirement for external funding. The Trustees have reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. They continue to believe the going concern basis of accounting is appropriate in preparing the annual financial statements. This is despite the effects of COVID-19 as delivery of educational workshops are to return to face to face events in the next financial year.

2.3 Income

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

2.4 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the charity's objectives, as well as any associated support costs.

Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

BRITISH SARCOMA GROUP**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2022****2. Accounting policies (continued)****2.5 Debtors**

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

2.6 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

2.7 Liabilities

Liabilities are recognised when there is an obligation at the balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

2.8 Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

2.9 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

BRITISH SARCOMA GROUP

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2022

3. Income from charitable activities

	Unrestricted funds 2022 £	Restricted funds 2022 £	Total funds 2022 £
Delegate Fees	59,020	-	59,020
Exhibitor fees	2,968	-	2,968
Sponsorship - Immedica Pharma	-	14,995	14,995
Sponsorship - PolyNovo UK Limited	-	2,247	2,247
Sponsorship - Bayer Plc	-	8,500	8,500
Sponsorship - Takeda UK Ltd	-	5,995	5,995
Sponsorship - Blueprint Medicines	-	-	-
Sponsorship - GSK UK	-	-	-
Sponsorship - Karyopharm Therapeutics	-	-	-
Sponsorship - Stryker European Operations Ltd	-	2,500	2,500
Sponsorship - Boston Scientific Ltd	-	2,995	2,995
Sponsorship - IGEA Medical	-	1,975	1,975
Total 2022	61,988	39,207	101,195
	Unrestricted funds 2021 £	Restricted funds 2021 £	Total funds 2021 £
Delegate Fees	11,250	-	11,250
Sponsorship - Immedica Pharma	-	6,000	6,000
Sponsorship - Bayer Plc	-	5,000	5,000
Sponsorship - Takeda UK Ltd	-	4,000	4,000
Sponsorship - Blueprint Medicines	-	2,000	2,000
Sponsorship - GSK UK	-	2,000	2,000
Sponsorship - Karyopharm Therapeutics	-	2,000	2,000
Total 2021	11,250	21,000	32,250

BRITISH SARCOMA GROUP

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2022

4. Analysis of grants

	Grants to Institutions 2022 £	Total funds 2022 £
	<i>Grants to Institutions 2021 £</i>	<i>Total funds 2021 £</i>
Grants, Annual conference	1,450	1,450

5. Analysis of expenditure on charitable activities

Summary by fund type

	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
Annual conference	60,203	39,207	99,410

	<i>Unrestricted funds 2021 £</i>	<i>Restricted funds 2021 £</i>	<i>Total 2021 £</i>
Annual conference	21,190	20,987	42,177

6. Analysis of expenditure by activities

	Activities undertaken directly 2022 £	Support costs 2022 £	Total funds 2022 £
Annual conference	74,282	25,128	99,410

BRITISH SARCOMA GROUP

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2022

6. Analysis of expenditure by activities (continued)

	<i>Activities undertaken directly 2021 £</i>	<i>Grant funding of activities 2021 £</i>	<i>Support costs 2021 £</i>	<i>Total funds 2021 £</i>
Annual conference	26,118	1,450	14,609	42,177

Analysis of direct costs

	Annual conference 2022 £	Total funds 2022 £
Conference costs	54,282	54,282
Secretariat fees	20,000	20,000
	74,282	74,282

	<i>Annual conference 2021 £</i>	<i>Total funds 2021 £</i>
Conference costs	12,118	12,118
Secretariat fees	14,000	14,000
	26,118	26,118

BRITISH SARCOMA GROUP

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2022

6. Analysis of expenditure by activities (continued)

Analysis of support costs

	Annual conference 2022 £	Total funds 2022 £
Bank charges	813	813
NSF Membership services and database fee	2,920	2,920
Other support costs	1,596	1,596
Irrecoverable VAT	8,234	8,234
Independent examination fees - governance cost	1,565	1,565
Association management	10,000	10,000
	<u>25,128</u>	<u>25,128</u>
	Annual conference 2021 £	Total funds 2021 £
Bank charges	211	211
NSF Membership services and database fee	2,920	2,920
Other support costs	178	178
Independent examination fees - governance cost	1,300	1,300
Association management	10,000	10,000
	<u>14,609</u>	<u>14,609</u>

7. Independent examiner's remuneration

	2022 £	2021 £
Fees payable to the charity's independent examiner for the preparation and independent examination of the charity's annual accounts	<u>1,330</u>	<u>1,300</u>

8. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2021 - £NIL).

During the year ended 31 March 2022, expenses totalling £707 were reimbursed or paid directly to 1 Trustee (2021 - £NIL). Expenses reimbursed related to cost of board meal.

BRITISH SARCOMA GROUP

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2022

9. Debtors

	2022 £	2021 £
Due within one year		
Trade debtors	7,629	252
Other debtors	253	3,363
	<u>7,882</u>	<u>3,615</u>

10. Creditors: Amounts falling due within one year

	2022 £	2021 £
Trade creditors	44,404	1,755
Other taxation and social security	474	-
Accruals and deferred income	2,045	2,600
	<u>46,923</u>	<u>4,355</u>

11. Financial instruments

	2022 £	2021 £
Financial assets		
Financial assets measured at fair value through income and expenditure	<u>143,518</u>	<u>103,432</u>

Financial assets measured at fair value through income and expenditure comprise bank balances.

BRITISH SARCOMA GROUP

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2022

12. Statement of funds

Statement of funds - current year

	Balance at 1 April 2021 £	Income £	Expenditure £	Balance at 31 March 2022 £
Unrestricted funds				
General Funds	102,692	61,988	(60,203)	104,477
Restricted funds				
Restricted Fund	-	39,207	(39,207)	-
Total of funds	102,692	101,195	(99,410)	104,477

Statement of funds - prior year

	Balance at 1 April 2020 £	Income £	Expenditure £	Balance at 31 March 2021 £
Unrestricted funds				
General Funds	112,619	11,250	(21,177)	102,692
Restricted funds				
Restricted Fund	-	21,000	(21,000)	-
Total of funds	112,619	32,250	(42,177)	102,692

BRITISH SARCOMA GROUP

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2022

13. Analysis of net assets between funds

Analysis of net assets between funds - current year

	Unrestricted funds 2022 £	Total funds 2022 £
Current assets	151,400	151,400
Creditors due within one year	(46,923)	(46,923)
Total	<u>104,477</u>	<u>104,477</u>

Analysis of net assets between funds - prior year

	<i>Unrestricted funds 2021 £</i>	<i>Total funds 2021 £</i>
Current assets	107,047	107,047
Creditors due within one year	(4,355)	(4,355)
Total	<u>102,692</u>	<u>102,692</u>

14. Related party transactions

Several trustees attended the annual conference in the year and paid the appropriate attendance fee at the same rate as other delegates. There were no other related party transactions during the year.

Accounts

BRITISH SARCOMA GROUP

UNAUDITED

TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2021

BRITISH SARCOMA GROUP

CONTENTS

	Page
Reference and administrative details of the charity, its Trustees and advisers	1
Trustees' report	2 - 5
Independent examiner's report	6
Statement of financial activities	7
Balance sheet	8
Notes to the financial statements	9 - 17

BRITISH SARCOMA GROUP

REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 MARCH 2021

Trustees

Professor I Judson
Dr A Dangoor
Dr I Fragkandrea-Nixon
Mr C Gerrand
Mr A Hayes, President
Mrs A Pabla
Dr B Seddon
Mr O Tilsley
Ms A Z McCarthy
Mr P Cool (appointed 27 January 2021)

Charity registered number

1154928

Principal office

The Grainger Suite
Dobson House
Regent Centre
Newcastle upon Tyne
NE3 3PF

Secretary

Echo Events & Association Management

Accountants

Ryecroft Glenton
Chartered Accountants
32 Portland Terrace
Newcastle upon Tyne
NE2 1QP

Bankers

Lloyds Bank Plc
Ariel House
2138 Coventry Road
Sheldon
Birmingham
B26 3JW

BRITISH SARCOMA GROUP

TRUSTEES' REPORT FOR THE YEAR ENDED 31 MARCH 2021

The Trustees present their annual report together with the financial statements of the charity for the year from 1 April 2020 to 31 March 2021.

The financial statements have been prepared in accordance with the accounting policies set out in the notes to the financial statements and comply with the charity's governing document, the Charities Act 2011 and the relevant version of the Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

Objectives and activities

● Policies and objectives

In setting objectives and planning for activities, the Trustees have given due consideration to general guidance published by the charity commission relating to public benefit.

The objectives of the British Sarcoma Group are: -

1. the relief of sickness by maintaining and advancing the education of medical, nursing and healthcare professionals in the United Kingdom concerned with the treatment and care of patients with bone and soft tissue sarcomas, through the provision of information, training and the identification of best practice;
2. the relief of sickness by the promotion of excellence in the healthcare and the treatment of patients with bone and soft tissue sarcoma, through enabling treatment specialists to identify and share best practice;
3. the relief of sickness and the preservation of health in particular by promoting and supporting research with the publication of the useful results thereof and the development of more effective treatment and care for patients with bone and soft tissue sarcomas; and
4. to advance the education of the medical profession and the general public in all areas relating to sarcoma.

● Main activities undertaken to further the charity's purposes for the public benefit

Providing information about best practice in sarcoma treatment via the website, email updates, reports and other publications.

Running a programme of training and educational events (conferences, workshops, study days) to identify and share best practice.

Running scientific meetings.

Developing and promoting nationally-recognised and adopted clinical guidelines and service standards for the management of sarcoma.

Providing expert representation on sarcoma to the NHS through written responses and membership of advisory groups.

Developing projects to improve sarcoma healthcare and treatment.

Informing medical professionals about new research; promoting opportunities for research; commissioning research into best practice.

Providing information and training to generalist medical professionals about sarcoma.

BRITISH SARCOMA GROUP

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2021

Objectives and activities (continued)

Working with other professional bodies and Royal Colleges to develop joint educational initiatives.

Working with national sarcoma patient organisations to raise awareness of sarcoma amongst public.

Achievements and performance

● Review of activities

The main achievements of the BSG in this financial year were to deliver the virtual annual conference, the major UK forum for multidisciplinary education in sarcoma and to continue to deliver nationally recognised clinical guidelines for the management of sarcoma.

Financial review

● Going concern

After making appropriate enquiries, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. This is despite the effects of COVID-19 as delivery of educational workshops are to return to face to face events in the next financial year. For this reason, they continue to adopt the going concern basis in preparing the financial statements. Further details regarding the adoption of the going concern basis can be found in the Accounting Policies.

● Reserves policy

The total funds of the charity at 31 March 2021 were £102,692.

The Board of Trustees have agreed it is necessary to maintain a level of reserves to cover the administration costs and the cost of staging the annual conference. This averages approximately £70,000 in total. The Trustees are pleased to note that the total funds exceed this figure and have plans to use these as explained in the future developments section of this Report.

● Overview

Income for the year totalled £32,250. The Statement of Financial Activities shows that the main source of income is sponsorship and delegate fees from the annual conference.

Delegate fees are shown under the general fund as unrestricted funds. Total delegate fees for the year were £11,250 (34.9% of total income).

Sponsorship income is restricted at the request of the donor. Total sponsorship for the year was £21,000 (65.1% of total income). A full breakdown of sponsors is given in note 3.

Expenditure for the year totalled £42,177. The Statement of Financial Activities shows that the main areas of expenditure are charitable activities.

An operating deficit of £9,927 (previous year: surplus of £8,002) was made this year and decreases the total general unrestricted funds of the charity at 31 March 2021 to £102,692 (previous period: £112,619).

BRITISH SARCOMA GROUP

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2021

Structure, governance and management

• Constitution

The British Sarcoma Group (BSG) is a Charitable Incorporated Organisation (CIO) registered in England and Wales with the Charity Commission on 8 December 2013. Its governing document is its constitution, adopted 22 May 2013.

• Methods of appointment or election of Trustees

Trustees are appointed by the existing Trustees for a three-year term which is extendable by mutual agreement of other Trustees with a maximum extension of a further three years. This is dependent on the skill set offered by the board member and the need to retain a wide range of key skills relevant to the continued success of the charity. New Trustees receive the BSG constitution, published accounts, minutes of previous Board of Trustee meetings, as well as the Charity Commission guidance on effective governance.

Trustees meet on average three times a year in person or by teleconference.

• Organisational structure and decision-making policies

The day-to-day administration of the British Sarcoma Group and BSG conference management is delivered by Echo AM Limited.

• Financial risk management

The Trustees have assessed the major risks to which the charity is exposed, in particular those related to the operations and finances of the charity, and are satisfied that systems and procedures are in place to mitigate exposure to the major risks.

Plans for future periods

In addition to the continuing activities referred to earlier in this Report the Trustees plan to spend funds in the 2021/22 year on a return to face to face educational workshops on initiatives to bring the sarcoma community together.

BRITISH SARCOMA GROUP**TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2021****Statement of Trustees' responsibilities**


The Trustees are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charity's transactions and disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the Trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the members of the board of Trustees on 24 January 2022 and signed on their behalf by:

DocuSigned by:

1710C365D69E409...

Mr A Hayes MA PhD FRCS (Gen)
President

BRITISH SARCOMA GROUP**INDEPENDENT EXAMINER'S REPORT
FOR THE YEAR ENDED 31 MARCH 2021****Independent examiner's report to the Trustees of British Sarcoma Group ('the charity')**

We report to the charity Trustees on our examination of the accounts of the charity for the year ended 31 March 2021.

Responsibilities and basis of report

As the Trustees of the charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').

We report in respect of our examination of the charity's accounts carried out under section 145 of the 2011 Act and in carrying out our examination we have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

Your attention is drawn to the fact that the charity has prepared the financial statements in accordance with the relevant version of the Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). This is in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has been withdrawn.


We understand that this has been done in order for the accounts to provide a true and fair view in accordance with the Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2019.

We have completed our examination. We confirm that no matters have come to our attention in connection with the examination giving us cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 130 of the 2011 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

We have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

This report is made solely to the charity's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our work has been undertaken so that we might state to the charity's Trustees those matters we are required to state to them in an Independent examiner's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's Trustees as a body, for our work or for this report.

Signed: 
Detlev Anderson FCA

Dated: 24 January 2022

Ryecroft Glenton
32 Portland Terrace
Newcastle upon Tyne
NE2 1QP

BRITISH SARCOMA GROUP

STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 MARCH 2021

	Note	Unrestricted funds 2021 £	Restricted funds 2021 £	Total funds 2021 £	Total funds 2020 £
Income from:					
Charitable activities	3	11,250	21,000	32,250	103,695
Total income		11,250	21,000	32,250	103,695
Expenditure on:					
Charitable activities	5	21,177	21,000	42,177	95,693
Total expenditure		21,177	21,000	42,177	95,693
Net movement in funds		(9,927)	-	(9,927)	8,002
Reconciliation of funds:					
Total funds brought forward		112,619	-	112,619	104,617
Net movement in funds		(9,927)	-	(9,927)	8,002
Total funds carried forward		102,692	-	102,692	112,619

The Statement of financial activities includes all gains and losses recognised in the year.

The notes on pages 9 to 17 form part of these financial statements.

BRITISH SARCOMA GROUP

BALANCE SHEET
AS AT 31 MARCH 2021

	Note	2021 £	2020 £
Current assets			
Debtors	9	3,615	3,046
Cash at bank and in hand		103,432	129,915
		<u>107,047</u>	<u>132,961</u>
Creditors: amounts falling due within one year	10	(4,355)	(20,342)
Net current assets		<u>102,692</u>	<u>112,619</u>
Total assets less current liabilities		<u>102,692</u>	<u>112,619</u>
Total net assets		<u>102,692</u>	<u>112,619</u>
Charity funds			
Restricted funds	12	-	-
Unrestricted funds	12	102,692	112,619
Total funds		<u>102,692</u>	<u>112,619</u>

The financial statements were approved and authorised for issue by the Trustees on 24 January 2022 and signed on their behalf by:

DocuSigned by:

 1710C365D69E409...

Mr A Hayes MA PhD FRCS (Gen)
President

The notes on pages 9 to 17 form part of these financial statements.

BRITISH SARCOMA GROUP

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2021

1. General information

British Sarcoma Group is a charitable entity, charity number 1154928. The registered office is Grainger Street, Dobson House, Regent Centre, Newcastle upon Tyne, NE3 3PF.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the relevant version of the Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011 and UK Generally Accepted Accounting Practice.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair view'. This departure has involved following the relevant version of the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

British Sarcoma Group meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

2.2 Going concern

The charity has cash resources and no requirement for external funding. The Trustees have reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. They continue to believe the going concern basis of accounting is appropriate in preparing the annual financial statements. This is despite the effects of COVID-19 as delivery of educational workshops are to return to face to face events in the next financial year.

2.3 Income

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

2.4 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the charity's objectives, as well as any associated support costs.

Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

BRITISH SARCOMA GROUP**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2021****2. Accounting policies (continued)****2.5 Debtors**

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

2.6 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

2.7 Liabilities

Liabilities are recognised when there is an obligation at the balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

2.8 Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

2.9 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

BRITISH SARCOMA GROUP

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2021

3. Income from charitable activities

	Unrestricted funds 2021 £	Restricted funds 2021 £	Total funds 2021 £
Delegate Fees	11,250	-	11,250
Takeda UK Ltd	-	4,000	4,000
Bayer Plc	-	5,000	5,000
Blueprint Medicines	-	2,000	2,000
GSK UK	-	2,000	2,000
Karyopharm Therapeutics	-	2,000	2,000
Stryker European Operations Ltd	-	-	-
Immedica Pharma	-	6,000	6,000
Total 2021	11,250	21,000	32,250

	Unrestricted funds 2020 £	Restricted funds 2020 £	Total funds 2020 £
Delegate Fees	67,900	-	67,900
Takeda UK Ltd	-	7,000	7,000
Bayer Plc	-	7,000	7,000
Blueprint Medicines	-	3,600	3,600
Karyopharm Therapeutics	-	2,100	2,100
Stryker European Operations Ltd	-	2,100	2,100
Immedica Pharma	-	13,995	13,995
Total 2020	67,900	35,795	103,695

4. Analysis of grants

	Grants to Institutions 2021 £	Total funds 2021 £	Total funds 2020 £
Grants	1,450	1,450	-

BRITISH SARCOMA GROUP**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2021****5. Analysis of expenditure on charitable activities****Summary by fund type**

	Unrestricted funds 2021 £	Restricted funds 2021 £	Total funds 2021 £
Annual conference	21,177	21,000	42,177
	<u> </u>	<u> </u>	<u> </u>
	<i>Unrestricted funds 2020 £</i>	<i>Restricted funds 2020 £</i>	<i>Total funds 2020 £</i>
Annual conference	59,898	35,795	95,693
	<u> </u>	<u> </u>	<u> </u>

6. Analysis of expenditure by activities

	Activities undertaken directly 2021 £	Grant funding of activities 2021 £	Support costs 2021 £	Total funds 2021 £
Annual conference	26,131	1,450	14,596	42,177
	<u> </u>	<u> </u>	<u> </u>	<u> </u>
	<i>Activities undertaken directly 2020 £</i>		<i>Support costs 2020 £</i>	<i>Total funds 2020 £</i>
Annual conference	70,955		24,738	95,693
	<u> </u>		<u> </u>	<u> </u>

BRITISH SARCOMA GROUP**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2021****6. Analysis of expenditure by activities (continued)****Analysis of direct costs**

	Annual conference 2021 £	Total funds 2021 £
Conference costs	12,131	12,131
Secretariat fees	14,000	14,000
	<u>26,131</u>	<u>26,131</u>

	<i>Annual conference 2020 £</i>	<i>Total funds 2020 £</i>
Conference costs	50,955	50,955
Secretariat fees	20,000	20,000
	<u>70,955</u>	<u>70,955</u>

Analysis of support costs

	Annual conference 2021 £	Total funds 2021 £
Bank charges	211	211
NSF Membership services and database fee	2,920	2,920
Other support costs	165	165
Independent examination fees - governance cost	1,300	1,300
Association management	10,000	10,000
	<u>14,596</u>	<u>14,596</u>

BRITISH SARCOMA GROUP

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2021

6. Analysis of expenditure by activities (continued)

Analysis of support costs (continued)

	Annual conference 2020 £	Total funds 2020 £
Bank charges	823	823
NSF Membership services and database fee	2,920	2,920
Other support costs	882	882
Irrecoverable VAT	8,913	8,913
Independent examination fees - governance cost	1,200	1,200
Association management	10,000	10,000
	<u>24,738</u>	<u>24,738</u>

7. Independent examiner's remuneration

	2021 £	2020 £
Fees payable to the charity's independent examiner for the preparation and independent examination of the charity's annual accounts	<u>1,300</u>	<u>1,200</u>

8. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2020 - £NIL).

During the year, no Trustee expenses have been incurred (2020 - £197 reimbursed to two Trustees).

9. Debtors

	2021 £	2020 £
Due within one year		
Trade debtors	252	933
Other debtors	3,363	1,866
Prepayments and accrued income	-	247
	<u>3,615</u>	<u>3,046</u>

BRITISH SARCOMA GROUP

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2021

10. Creditors: Amounts falling due within one year

	2021 £	2020 £
Trade creditors	1,755	19,142
Accruals and deferred income	2,600	1,200
	<u>4,355</u>	<u>20,342</u>

11. Financial instruments

	2021 £	2020 £
Financial assets		
Financial assets measured at fair value through income and expenditure	<u>103,432</u>	<u>129,915</u>

Financial assets measured at fair value through income and expenditure comprise bank balances.

BRITISH SARCOMA GROUP

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2021

12. Statement of funds

Statement of funds - current year

	Balance at 1 April 2020 £	Income £	Expenditure £	Balance at 31 March 2021 £
Unrestricted funds				
General Funds	112,619	11,250	(21,177)	102,692
Restricted funds				
Restricted Fund	-	21,000	(21,000)	-
Total of funds	112,619	32,250	(42,177)	102,692

Statement of funds - prior year

	Balance at 1 April 2019 £	Income £	Expenditure £	Balance at 31 March 2020 £
Unrestricted funds				
General Funds	104,617	67,900	(59,898)	112,619
Restricted funds				
Restricted Funds - all funds	-	35,795	(35,795)	-
Total of funds	104,617	103,695	(95,693)	112,619

BRITISH SARCOMA GROUP

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2021

13. Analysis of net assets between funds

Analysis of net assets between funds - current year

	Unrestricted funds 2021 £	Total funds 2021 £
Current assets	107,047	107,047
Creditors due within one year	(4,355)	(4,355)
Total	102,692	102,692

Analysis of net assets between funds - prior year

	Unrestricted funds 2020 £	Total funds 2020 £
Current assets	132,961	132,961
Creditors due within one year	(20,342)	(20,342)
Total	112,619	112,619

14. Related party transactions

There were no related party transactions during the year.